Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage radiopharmaceutical company, to develop targeted alpha therapies for various cancers. The partnership will leverage AdvanCell’s Pb-212 production technology and Lilly’s drug development expertise.
Collaboration Details
The agreement combines AdvanCell’s proprietary radionuclide infrastructure with Lilly’s drug candidate programs. The goal is to accelerate the development of an expanded portfolio of targeted alpha therapies, including novel Pb-212-based radiotherapeutics. Financial terms were not disclosed.
Strategic Outlook
The collaboration aims to advance innovative treatments for cancers, utilizing AdvanCell’s targeted alpha therapy platform. Lilly’s expertise in drug development will support the clinical advancement of these therapies.-Fineline Info & Tech
